PA8442401A1 - Inhibidores polipropilos de ciclofilina - Google Patents

Inhibidores polipropilos de ciclofilina

Info

Publication number
PA8442401A1
PA8442401A1 PA19978442401A PA8442401A PA8442401A1 PA 8442401 A1 PA8442401 A1 PA 8442401A1 PA 19978442401 A PA19978442401 A PA 19978442401A PA 8442401 A PA8442401 A PA 8442401A PA 8442401 A1 PA8442401 A1 PA 8442401A1
Authority
PA
Panama
Prior art keywords
inhibitors
cyclophiline
polypropyl
asin
activity
Prior art date
Application number
PA19978442401A
Other languages
English (en)
Inventor
Gregory S Hamilton
Ling Wei
Original Assignee
Guilford Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guilford Pharm Inc filed Critical Guilford Pharm Inc
Publication of PA8442401A1 publication Critical patent/PA8442401A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic

Abstract

ESTA INVENCION TRATA DE COMPUESTOS NEUROTROFICOS INHIBIDORES DE CICLOFILINA PEPTIDOS DE MOLECULAS PEQUEÑAS Y BAJO PESO MOLECULAR CON UNA AFINIDAD POR INMUNOFILINAS DE TIPO CICLOFILINA Y SU USO COMO INHIBIDORES DE LA ACTIVIDAD ENZIMATICA ASOCIADA CON LAS PROTEINAS DE INMUNOFILINAS, PARTICULARMENTE LA ACTIVIDAD ENZIMATICA DE LA ISOMERASA PEPTIDIL-PROPILO O ROTAMASA.
PA19978442401A 1996-12-09 1997-12-05 Inhibidores polipropilos de ciclofilina PA8442401A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76190296A 1996-12-09 1996-12-09

Publications (1)

Publication Number Publication Date
PA8442401A1 true PA8442401A1 (es) 2000-05-24

Family

ID=25063558

Family Applications (1)

Application Number Title Priority Date Filing Date
PA19978442401A PA8442401A1 (es) 1996-12-09 1997-12-05 Inhibidores polipropilos de ciclofilina

Country Status (8)

Country Link
EP (1) EP0966479A4 (es)
JP (1) JP2001505920A (es)
AR (1) AR010744A1 (es)
AU (1) AU5702698A (es)
CA (1) CA2263828A1 (es)
PA (1) PA8442401A1 (es)
WO (1) WO1998025950A1 (es)
ZA (1) ZA9710989B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200100122T2 (tr) 1998-07-17 2001-08-21 Agouron Pharmaceuticals.Inc. Nöral büyüme ve uzama için bileşikler, kompozisyonlar, yöntemler
AU5483500A (en) 1999-07-09 2001-01-30 Ortho-Mcneil Pharmaceutical, Inc. Neurotrophic 2-azetidinecarboxylic acid derivatives, and related compositions and methods
AU781235B2 (en) 1999-07-09 2005-05-12 Ortho-Mcneil Pharmaceutical, Inc. Neurotrophic pyrrolidines and piperidines, and related compositions and methods
US6323215B1 (en) 1999-07-09 2001-11-27 Ortho-Mcneil Pharmaceutical, Inc. Neurotrophic tetrahydroisoquinolines and tetrahydrothienopyridines, and related compositions and methods
CZ20022720A3 (cs) * 2000-02-11 2002-11-13 Vertex Pharmaceuticals Incorporated Deriváty piperazinu a piperidinu pro pouľití při léčení a prevenci poąkozených neuronů
GB0030378D0 (en) 2000-12-13 2001-01-24 Cyclacel Ltd Compound
US6593362B2 (en) 2001-05-21 2003-07-15 Guilford Pharmaceuticals Inc. Non-peptidic cyclophilin binding compounds and their use
EP3164148A4 (en) 2014-06-25 2017-12-13 Cold Spring Harbor Laboratory Methods and compositions for inhibiting growth and epithelial to mesenchymal transition (emt) in cancer cells
DK3774838T3 (da) 2018-04-10 2022-10-31 Sanofi Aventis Deutschland Lixisenatidsyntese med capping

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023077A (en) * 1989-01-24 1991-06-11 Aphton Corporation Immunogenic compositions and methods for the treatment and prevention of gastric and duodenal ulcer disease
JP2782142B2 (ja) * 1992-07-23 1998-07-30 カルピス株式会社 アンジオテンシン変換酵素阻害剤及びその製造法
IL106998A0 (en) * 1992-09-17 1993-12-28 Univ Florida Brain-enhanced delivery of neuroactive peptides by sequential metabolism
JP3089350B2 (ja) * 1995-11-20 2000-09-18 ギルフォード ファーマシューティカルズ インコーポレイテッド シクロフィリンロタマーゼ活性の阻害剤

Also Published As

Publication number Publication date
WO1998025950A1 (en) 1998-06-18
AR010744A1 (es) 2000-07-12
JP2001505920A (ja) 2001-05-08
CA2263828A1 (en) 1998-06-18
ZA9710989B (en) 1999-05-25
EP0966479A4 (en) 2004-12-08
EP0966479A1 (en) 1999-12-29
AU5702698A (en) 1998-07-03

Similar Documents

Publication Publication Date Title
PA8438401A1 (es) Tiosteres y cetonas heterociclicos
PA8438501A1 (es) Esteres y amidas heterociclicos
PA8446601A1 (es) Metodo de uso de compuestos neurotropicos de sulfonamidas
BR9708100A (pt) Proteìna alfa de ativação de fibroblasto dimérico isolado, e seus usos.
CR6392A (es) Moduladores de ccr5
ES2191152T3 (es) Terapia combinada para el tratamiento de psicosis.
BR9900320A (pt) Composição antimicrobiana
HN2002000154A (es) Azaindoles
ES2116594T3 (es) Ansamicinas biciclicas y su uso como agentes antitumorales.
EE200100102A (et) Mittepeptiidsed GnRH agensid, nende valmistamise meetodid ja vaheühendid
PT1169370E (pt) Solucoes de poliuretano contendo unidades estruturais de alcoxissilano.
ATE369346T1 (de) Halogenpyrimidinylaryl(thio)ether als pestizide
SE9802729D0 (sv) Novel Compounds
DK1097173T3 (da) Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
PA8442401A1 (es) Inhibidores polipropilos de ciclofilina
PT1028950E (pt) Quinazolina-2,4-dionas 7-substituidas uteis como agentes antibacterianos
PA8444001A1 (es) Ureas y carbamatos de tioesteres heterociclicos con enlace n
NO20031860D0 (no) Kahalaolid F
ES2193197T3 (es) Craquizacion catalitica com mcm-49.
BR0115080A (pt) Derivados de acila e sulfonila de 2-(trans-1,4-diaminocicloexil)-purinas 6,9-dissubstituìdas e o uso destes como agentes antiproliferativos
SV2002000041A (es) Derivados de resorcinol ref. pc10529/82897/bb
MY127474A (en) Naphthyl compounds, intermediates, compositions, and methods of use
EA200000875A1 (ru) Белки, взаимодействующие с каспазой-8
ATE279282T1 (de) Metallschaumkörper auf basis von zink
ATE246690T1 (de) Thiazolopyrimidine verwendbar als tnf-alpha inhibitoren